Patents Issued in February 18, 2014
-
Patent number: 8653257Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.Type: GrantFiled: April 12, 2012Date of Patent: February 18, 2014Assignee: Astrazeneca ABInventors: Dean Brown, James R. Damewood, Phil Edwards, James Hulsizer, James Campbell Muir, M. Edward Pierson, Jr., Ashokkumar Bhikkappa Shenvi, Steven Wesolowski, Dan Widzowski, Michael Wood
-
Patent number: 8653258Abstract: The present disclosure encompasses compounds and compositions that are useful as specific AI-2 antagonists for the control of bacterial quorum sensing. Although the AI-2 antagonists according to the present disclosure may not have bactericidal effect, their ability to attenuate virulence, drug resistance, and/or biofilm formation have therapeutic benefits. In addition, the AI-2 antagonists of the present disclosure can also be used as tools to probe bacterial AI-2 functions. The present disclosure also encompasses methods for inhibiting or attenuating microbial virulence, biofilm formation, and drug resistance. The methods are suitable for preventing bacteria from accruing and forming extensive biofilms that may be a health or hygiene hazard or a physical issue, such as in the blockage of water or fuel lines.Type: GrantFiled: June 6, 2008Date of Patent: February 18, 2014Assignee: Georgia State University Research Foundation, Inc.Inventors: Binghe Wang, Nanting Ni, Junfeng Wang, Chung-Dar Lu, Han-Ting Chou, Minyong Li, Shilong Zheng, Yunfeng Cheng, Hanjing Peng
-
Patent number: 8653259Abstract: The invention provides the process illustrated in scheme 1 for synthesizing heterocyclic compounds of formula I. In the process, an isothiocyanate of formula II is initially reacted with a primary amine or formula III to give a thiourea of formula IV. Subsequently, the thiourea of formula IV is converted to the corresponding heterocycle of formula I using a base and a sulfonyl chloride.Type: GrantFiled: February 6, 2008Date of Patent: February 18, 2014Assignee: Sanofi-Aventis Deutschland GmbHInventors: Uwe Heinelt, Hans-Jochen Lang
-
Patent number: 8653260Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.Type: GrantFiled: June 20, 2012Date of Patent: February 18, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Richard Berger, Lehua Chang, Scott D. Edmondson, Stephen D. Goble, Sookhee Nicole Ha, Nam Fung Kar, Ihor E. Kopka, Bing Li, Gregori J. Morriello, Chris R. Moyes, Ding-Ming Shen, Liping Wang, Cheng Zhu
-
Patent number: 8653261Abstract: Actinomysin-based near IR emitting compounds and methods of their use as nucleic acid stains are provided. The actinomysin-based near IR emitting compounds have the structure: wherein R is H or NH2; R1, R2, R3, and R4 are independently a moiety comprising 1-30 atoms selected from H, O, C, and N, wherein the atoms are in a linear, branched, or cyclic configuration; R3 and/or R4 comprise a quaternary nitrogen atom; and R5 is H, F, or Cl.Type: GrantFiled: October 26, 2009Date of Patent: February 18, 2014Assignee: Life Technologies CorporationInventors: Stephen Yue, Jixiang Liu, Jolene Bradford
-
Patent number: 8653262Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.Type: GrantFiled: May 29, 2008Date of Patent: February 18, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Heiner Ebel, Silke Hobbie
-
Patent number: 8653263Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.Type: GrantFiled: October 21, 2010Date of Patent: February 18, 2014Assignee: Janssen PharmaceuticaInventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode-Johnson, Emily M. Stocking, Devin M. Swanson
-
Patent number: 8653264Abstract: A novel crystal of antitumor drug erlotinib base and its preparation method are provided in the present invention. A preparation method of erlotinib hydrochloride with high-purity is also provided in the present invention.Type: GrantFiled: August 12, 2011Date of Patent: February 18, 2014Assignee: Zhejiang Huahai Pharmaceutical Co., Ltd.Inventors: Ke Xiang, Min Xu
-
Patent number: 8653265Abstract: A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.Type: GrantFiled: May 27, 2009Date of Patent: February 18, 2014Assignee: Changzhou Pharmaceutical FactoryInventors: Benshun Chen, Bing Wang, Xiaofeng Jin, Lin Zou
-
Patent number: 8653266Abstract: A novel process for the preparation of Etravirine comprises the condensing of ethyl cyanoacetate with N-cyanophenylguanidine to obtain an —OH compound of formula (II), which is further converted to a leaving group of formula (III). The compound of formula (III) is optionally protected and brominated to yield compound of formula (IV). The condensation of formula (IV) with 3,5-dimethyl-4-hydroxybenzonitrile yields a compound of formula (VI), and an optional deprotection of the compound of formula (VI) results in Etravirine.Type: GrantFiled: April 26, 2012Date of Patent: February 18, 2014Assignee: Mylan Laboratories LimitedInventors: Vinayak Gore, Choudhari Bharati, Mahesh Hublikar, Prakash Bansode, Sandip Sinore
-
Patent number: 8653267Abstract: The present invention discloses a co-crystal compound of optical devices. The co-crystal compound is crystallized out with hydrogen bonding by a temperature fluctuation method after mixing small organic molecules without optoelectronic properties and organic molecules having heterocyclic rings with optoelectronic properties. The photoluminescence (PL) intensity of this hydrogen-bonded co-crystal compound according to the present invention can vary with a variety of the small organic molecules without optoelectronic properties, so as to modulate the PL intensity.Type: GrantFiled: May 11, 2010Date of Patent: February 18, 2014Assignee: National Central UniversityInventors: Tu Lee, Pu-Yun Wang
-
Patent number: 8653268Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.Type: GrantFiled: January 11, 2013Date of Patent: February 18, 2014Assignee: OSI Pharmaceuticals, LLCInventors: Mark J. Mulvihill, Radoslaw Laufer, An-Hu Li, Arno G. Steinig
-
Patent number: 8653269Abstract: Provided is a process for the preparation of t-butoxycarbonylamine compounds, which comprises using phosgene or a phosgene equivalent, t-butanol, and an organic base. Even when applied to a primary or secondary amine compound having low nucleophilicity, the process enables highly selective preparation of a t-butoxycarbonylamine compound at a low cost. In the process, a t-butoxycarbonylamine compound is prepared using: phosgene or a phosgene equivalent; t-butanol; an organic base; and either a primary or secondary amine compound or a primary or secondary ammonium salt.Type: GrantFiled: March 8, 2011Date of Patent: February 18, 2014Assignee: Nippon Soda Co., Ltd.Inventors: Hiroki Inoue, Kaoru Noda
-
Patent number: 8653270Abstract: The present invention relates to novel derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: November 18, 2011Date of Patent: February 18, 2014Assignee: Allergan, Inc.Inventors: Todd M. Heidelbaugh, Phong X. Nguyen
-
Patent number: 8653271Abstract: The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist.Type: GrantFiled: October 18, 2007Date of Patent: February 18, 2014Assignee: University of Kentucky Research FoundationInventors: Audra L. Stinchcomb, Peter A. Crooks, Mohamed O. Hamad, Paul K. Kiptoo
-
Patent number: 8653272Abstract: A series of heteroaryl-substituted fused pyridine derivatives, in particular heteroaryl-substituted thieno[3,2-6]pyridine derivatives, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: GrantFiled: October 21, 2009Date of Patent: February 18, 2014Assignee: UCB Pharma S.A.Inventors: Kerry Jenkins, Christopher James Lock, Andrew James Ratcliffe
-
Patent number: 8653273Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.Type: GrantFiled: July 7, 2011Date of Patent: February 18, 2014Assignee: The Trustees of Columbia University in the city of New YorkInventors: Kirsten Alison Rinderspacher, Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng
-
Patent number: 8653274Abstract: The present invention relates to novel derivatives that are suitable as precursors to compounds that are useful for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. The compounds deriving from these precursors are useful in methods of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease by positron emission tomography (PET) as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. Furthermore, the present invention also discloses the precursor compounds in crystalline form.Type: GrantFiled: June 4, 2012Date of Patent: February 18, 2014Assignee: AstraZeneca ABInventors: Seth Bjork, Vern Delisser, Peter Johnstrom, Nils Anders Nilsson, Katinka Ruda, Per Magnus Schou, Britt-Marie Swahn
-
Patent number: 8653275Abstract: Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.Type: GrantFiled: May 11, 2007Date of Patent: February 18, 2014Assignee: University of Kentucky Research FoundationInventors: Peter Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, Davis D. Allen, Zhenfa Zheng, Paul Lockman
-
Patent number: 8653276Abstract: The present invention is directed to compounds of the general formula: as defined herein, and pharmaceutical compositions thereof. The invention is also directed to their therapeutic use as urotensin II receptor antagonists, e.g., in the treatment of cardiac, coronary, and central nervous system disorders. In particular embodiments, the invention relates to 5,6-bisaryl-2-pyridinecarboxamides, to their preparation and to their therapeutic use as urotensin II receptor antagonists.Type: GrantFiled: May 15, 2013Date of Patent: February 18, 2014Assignee: SANOFIInventors: Jean-Michel Altenburger, Valerie Fossey, Daniel Galtier, Frederic Petit
-
Patent number: 8653277Abstract: It is to provide a fungicidal composition having stable and high fungicidal effects against cultivated crops infected with plant diseases resulting from plant diseases.Type: GrantFiled: May 29, 2009Date of Patent: February 18, 2014Assignee: Ishihara Sangyo Kaisha, Ltd.Inventors: Hisaya Nishide, Shigeyuki Nishimura, Shigeru Mitani, Koji Minamida, Fumio Kanamori, Munekazu Ogawa, Shigehisa Kanbayashi, Toyoshi Tanimura, Koji Higuchi, Hidemasa Kominami, Tomohiro Okamoto, Akihiro Nishimura
-
Patent number: 8653278Abstract: One aspect of the invention relates to isoform-selective HDAC inhibitors. Also provided are methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy. The invention also provides methods for treating cancer, methods for treating neurological diseases and methods for treating malaria. Additionally, the invention provides pharmaceutical compositions comprising an HDAC inhibitor of the invention; and kits comprising an HDAC inhibitor of the invention.Type: GrantFiled: August 2, 2007Date of Patent: February 18, 2014Assignees: Georgetown University, The Board of Trustees of the University of IllinoisInventors: Alan P. Kozikowski, Mira Jung, Anatoly Dritschilo, Arsen Gaysin, Pavel A. Petukhov, Werner Tueckmantel, Hongbin Yuan, Yufeng Chen
-
Patent number: 8653279Abstract: The present embodiments relate to a dye for a dye-sensitized solar cell and a dye-sensitized solar cell prepared from the same. The dye includes a fluorenyl-containing compound. The dye according to the present embodiments is applied to a light absorption layer to improve photovoltaic efficiency and increase an open-circuit voltage.Type: GrantFiled: April 16, 2007Date of Patent: February 18, 2014Assignee: Samsung SDI Co., Ltd.Inventors: Jae-Kwan Lee, Ji-Won Lee, Jae-Jung Ko, Sang-Hoon Kim, Soo-Jin Moon, Moon-Sung Kang, Moon-Seok Kwon
-
Patent number: 8653280Abstract: The present invention is directed to novel compounds of formula (I) as well as to the process for their preparation. Novel compounds of formula (I) can be converted into asenapine through an efficient process. The invention also relates to novel intermediates used in this process and their use in the preparation of compounds of formula (I).Type: GrantFiled: July 29, 2011Date of Patent: February 18, 2014Assignee: Laboratories Lesvi, S.L.Inventors: Pere Dalmases Barjoan, Juan Huguet Clotet, Jordi Peirats Masia
-
Patent number: 8653281Abstract: A process for the manufacture of agomelatine and its intermediate N-[2-(7-methoxy- 1-naphthy)ethyl]phthalimide is provided and inclues reacting 7-methoxy-1-naphthyl ethanol (III) with benzenesulfonyl chloride to obtain 7-methoxy-1 -naphthylethyl benzene sulfonate (IV), which is reacted with potassium phthalimide to produce N-[2-(7-methoxy-1-naphthy)ethyl]phthalimide (II); and subjecting N-[2-(7-methoxy-1-naphthy)ethyl]phthalimide (II) to alkaline hydrolysis and acetylation, to obtain agomelatine.Type: GrantFiled: July 23, 2009Date of Patent: February 18, 2014Assignee: NHWA Pharma. CorporationInventors: Guisen Zhang, Daopeng Chen, Yanqin Ma, Xiangping Yang, Shixia Zhou, Liang Chen
-
Patent number: 8653282Abstract: The invention relates to improved methods of preparing dihydrothienopyrimidines of formula 1, and intermediates thereof, (I) wherein X is SO or SO2, preferably SO, and wherein RA, R1, R2, R3, R4 and R5 have the meanings given in the description. The methods according to this invention are more suitable for large-scale synthesis of said compounds than prior methods because the new synthetic process avoids distillation and chromatographic purification between steps and results in a higher overall yield of the desired product.Type: GrantFiled: October 15, 2008Date of Patent: February 18, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Rogelio Frutos, Dhileepkumar Krishnamurthy, Jason Alan Mulder, Sonia Rodriguez, Chris Hugh Senanayake, Thomas G. Tampone
-
Patent number: 8653283Abstract: The present disclosure relates generally to compositions and methods for treating cancer. In some aspects, novel spirohexenolides and methods of using and producing them are described.Type: GrantFiled: April 16, 2010Date of Patent: February 18, 2014Assignee: The Regents of The University of CaliforniaInventors: Michael D. Burkart, James J. La Clair, MinJin Kang, Brian D. Jones, Alexander L. Mandel, Wei-Luen Yu, Justin C. Hammons
-
Patent number: 8653284Abstract: This invention provides a novel class of compounds and compositions and synthetic methods related to lactone antioxidant 3-arylbenzofuranones. The compounds may be useful to prevent yellowing and deterioration of organic materials preferably polymers, such as polyurethane foams as one example. The lactone antioxidants may be polymeric, and may also be liquid or paste in physical form at room temperature. Although it is not necessary for its stabilizing properties, the compositions may, in some species, bear one or more reactive primary OH groups on the polymer chains. The chains may also contain oligomeric oxyalkylene ether and aliphatic ester functional groups, in one embodiment of the invention.Type: GrantFiled: September 18, 2009Date of Patent: February 18, 2014Assignee: Milliken & CompanyInventor: Jusong Xia
-
Patent number: 8653285Abstract: An aminopropylidene derivative having excellent histamine receptor antagonistic action, a compound which is useful as a pharmaceutical composition, especially as an active ingredient, having alleviated side effects in the central nervous system is described. In the aminopropylidene derivative, R1 and R2, which may be identical or different, stand for a hydrogen, a substituted carbonyl, a substituted carbonylalkyl, and acrylic acid, excluding a case where both are hydrogen; R3 and R4, which may be identical or different, stand for hydrogen, an alkyl which may be substituted with phenyl, or the like; A stands for unsubstituted or an oxo; B stands for a carbon or an oxygen; one of X and Y stands for a carbon and the other stands for a sulfur, a broken line part stands for a single bond or a double bond, and a wavy line stands for cis-form and/or trans-form.Type: GrantFiled: July 31, 2009Date of Patent: February 18, 2014Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Kunihiko Higashiura, Takashi Ogino, Taizo Ito, Koji Kunimasu, Kazuhito Furukawa
-
Patent number: 8653286Abstract: Methods for forming maleimide functionalized polymers are provided. In one such embodiment, a maleimide functionalized polymer is prepared in a method that includes a step of carrying out a reverse Diels-Alder reaction. Intermediates useful in the methods, as well as methods for preparing the intermediates, are also provided. Also provided are polymeric reagents, methods of using polymeric reagents, compounds and conjugates.Type: GrantFiled: August 7, 2012Date of Patent: February 18, 2014Assignee: Nektar TherapeuticsInventors: Samuel P. McManus, Antoni Kozlowski, Tracy L. Hutchison, Brian Bray, Xiaoming Shen
-
Patent number: 8653287Abstract: A process is provided for the synthesis of furan and related compounds by liquid-phase decarbonylation of furfural and derivatives, using a palladium/metal aluminate catalyst. The compounds so produced can be used as starting materials for industrial chemicals for use as pharmaceuticals, herbicides, stabilizers, and polymers such as polyether ester elastomers and polyurethane elastomers.Type: GrantFiled: August 31, 2010Date of Patent: February 18, 2014Assignee: E I du Pont de Nemours and CompanyInventors: Ronnie Ozer, Ke Li
-
Patent number: 8653288Abstract: A process for making a deodorized edible oil or fat having a low level of bound MCPD (monochloro propanediol esters) and/or low level of bound 3-MCPD is described. The process comprises a step of contacting the oil or fat to a carboxymethyl cellulose or an ion exchange resin. The carboxymethyl cellulose can be a Blanose® cellulose gum and the resin can be a cationic resin. A deodorized vegetable oil or fat and a food product made there from is described. The food product can be an infant formula. It exhibits low levels of bound MCPD and/or low level of bound 3-MCPD. In one embodiment the oil or fat has a reduced level of free fatty acid as well as a limpid aspect and no off-flavors.Type: GrantFiled: July 19, 2010Date of Patent: February 18, 2014Assignee: Nestec S.A.Inventors: Constantin Bertoli, Francois Cauville, Annemarie Johanna Hendrika Schoonman
-
Patent number: 8653289Abstract: The present disclosure relates to specific (poly-)glycerol partial esters with at least one carboxylic acid and one polyfunctional carboxylic acid, and to the use thereof as emulsifier and to formulations comprising partial esters of the present disclosure.Type: GrantFiled: March 2, 2011Date of Patent: February 18, 2014Assignee: Evonik Goldschmidt GmbHInventors: Hans Henning Wenk, Juergen Meyer, Stefan Bergfried, Hannelore Foetsch
-
Patent number: 8653290Abstract: Disclosed are a metallocene complex represented by the general formula (I), (II) or (III), and a polymerization catalyst composition containing such a metallocene complex. In the formulae (I), (II) and (III), M represents a lanthanoid element, scandium or yttrium; CpR independently represents an unsubstituted or substituted indenyl; CpR? represents an unsubstituted or substituted cyclopentadienyl, indenyl or fluorenyl; Ra-Rf independently represents a hydrogen or an alkyl group having 1-3 carbon atoms; X and X? respectively represent a hydrogen atom, a halogen atom, an alkoxide group, a thiolate group, an amide group, a silyl group or a hydrocarbon group having 1-20 carbon atoms; L represents a neutral Lewis base; w represents an integer of 0-3; and [B]? represents a non-coordinating anion.Type: GrantFiled: May 2, 2007Date of Patent: February 18, 2014Assignees: Riken, Bridgestone Corporation, JSR CorporationInventors: Shojiro Kaita, Olivier Tardif
-
Patent number: 8653291Abstract: The invention relates to the use of disubstituted alkynes for the functionalisation of the surface of a substrate consisting of a semi-conductor material, with molecules of interest. According to the invention, a compound of formula A-(E1)n1-F1 is used, wherein A is a linear or cyclic disubstituted alkyne, E1 is an alkyl chain and n2 is 0 or 1, and F1 is a reactive group that can react with the reactive group F2 of a compound of formula F2-(E2)n2-X wherein E2 is an alkyl chain and X is a group having properties of interest. The invention is especially applicable to the field of molecular biology or biotechnology.Type: GrantFiled: March 16, 2010Date of Patent: February 18, 2014Assignee: Commissariat a l'Energie Atomique et aux Energies AlternativesInventors: Guillaume Delapierre, Regis Barattin, Aude Bernardin, Isabelle Texier-Nogues
-
Patent number: 8653292Abstract: The invention provides novel Zr MOFs, in particular compounds having a surface area of at least 1020 m2/g or if functionalized, having a surface area of at least 500 m2/g.Type: GrantFiled: April 29, 2009Date of Patent: February 18, 2014Assignee: Universitetet I OsloInventors: Jasmina Hafizovic, Unni Olsbye, Karl Petter Lillerud, Søren Jakobsen, Nathalie Guillou
-
Patent number: 8653293Abstract: A compound having the formula: Each R1 is C1-C3 alkyl group or fluoridated C1-C3 alkyl group. The value n is a positive integer. Each R2 is alkylene group or polyethylene glycol group. Y1 is hydrogen, quaternary ammonium containing group, or phenol-containing group. Y2 is quaternary ammonium-containing group or phenol-containing group. The quaternary ammonium-containing group is non-aromatic and contains no more than one quaternary ammonium.Type: GrantFiled: January 7, 2013Date of Patent: February 18, 2014Assignee: The United States of America, as represented by the Secretary of the NavyInventors: James H Wynne, Ramesh R. Pant
-
Patent number: 8653294Abstract: Novel silicone compounds containing a siloxane moiety and at least one terpenyl moiety, such as limonenyl or valencenyl, and methods for their synthesis, are provided. The novel compounds are appropriate for incorporation into cosmetic formulations due to their low aroma, resistance to deterioration, and favorable solubility properties.Type: GrantFiled: February 14, 2012Date of Patent: February 18, 2014Assignee: Gelest Technologies, Inc.Inventors: Barry C. Arkles, Rudolph Cameron, Youlin Pan, Gerald L. Larson
-
Patent number: 8653295Abstract: An ?-trifluoromethyl-?,?-unsaturated ester can be produced by reacting an ?-trifluoromethyl-?-hydroxy ester with sulfuryl fluoride (SO2F2) in the presence of an organic base. It is preferable that the raw substrate has a hydrogen atom as one ?-position substituent group and either an alkyl group, a substituted alkyl group, an alkenyl group, a substituted alkenyl group, an aromatic ring group or a substituted aromatic ring group as the other ?-position substituent group. It is more preferable that an ester moiety of the raw substrate is an alkyl ester. This raw substrate is readily available. Further, the desired reaction can proceed favorably with the use of this raw substrate. It is also preferable to use either 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) as the organic base. The desired reaction can proceed more favorably with the use of this organic base.Type: GrantFiled: September 24, 2009Date of Patent: February 18, 2014Assignee: Central Glass Company, LimitedInventors: Akihiro Ishii, Manabu Yasumoto, Takako Yamazaki, Kaori Mogi, Kazunori Mori, Takashi Masuda
-
Patent number: 8653296Abstract: A method for preparing esters of cyclohexane polycarboxylic acids from esters of benzene polycarboxylic acids makes improvement to hydrogenation of esters of benzene polycarboxylic acids by using a reaction tank having a gas-introducing mixer capable of extracting and exhausting air and stirring to hydrogenate an ester of a benzene polycarboxylic acids into an ester of a cyclohexane polycarboxylic acid in the presence of a hydrogenation catalyst; resulted in that the method advantageously minimizes the operational pressure for hydrogenating esters of benzene polycarboxylic acids and significantly lowers the reaction temperature for hydrogenation while effectively improving the yield of esters of cyclohexane polycarboxylic acids made from the esters of the benzene polycarboxylic acids.Type: GrantFiled: January 31, 2012Date of Patent: February 18, 2014Assignee: Nan Ya Plastics CorporationInventors: Dein-Run Fung, Jung-Jen Chuang, Chung-Yu Chen, Heng-Hua Hsiao
-
Patent number: 8653297Abstract: A solid acid having a core of calixarene or calix resorcinarene. The solid acid is an ion conducting compound in which at least one of the hydroxyl groups is substituted by an organic group having a cation exchange group at a terminal end, a polymer electrolyte membrane including the same, and a fuel cell using the polymer electrolyte membrane. The polymer electrolyte membrane can provide low methanol crossover and high ionic conductivity. Accordingly, a fuel cell having high efficiency can be obtained by using the polymer electrolyte membrane.Type: GrantFiled: September 21, 2011Date of Patent: February 18, 2014Assignee: Samsung SDI Co., Ltd.Inventors: Jae-jun Lee, Myung-sup Jung, Do-yun Kim, Jin-gyu Lee, Sang-kook Mah
-
Patent number: 8653298Abstract: The biphenyl acetate is biphenyl acetic ammonia butantriol salt, which is obtained by reacting biphenyl acetic acid with ammonia butantriol in organic solvent. The salt is adapted to be used for producing analgesic, anti-inflammatory and antithermic medicines.Type: GrantFiled: September 27, 2007Date of Patent: February 18, 2014Assignee: Shijiazhuang Yiling Pharmaceutical Co., Ltd.Inventors: Wei Wang, Wenzhan Chen
-
Patent number: 8653299Abstract: The present invention relates to novel dihydronaphthalene and naphthalene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.Type: GrantFiled: March 1, 2012Date of Patent: February 18, 2014Assignee: Allergan, Inc.Inventors: Vidyasagar Vuligonda, Richard L. Beard, Thong Vu, John E. Donello, Veena Viswanath, Michael E. Garst
-
Patent number: 8653300Abstract: A method for making a hindered phenolic antioxidant based on Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate uses a methanol solution containing alkali metal methoxide as a catalyst solution, wherein the catalyst solution is filtered with a filter device with a filter pore diameter of less than 50 ?m to remove insoluble matters therefrom before used in a transesterification process where methyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate and 1-Octadecanol are taken as reactants to obtain a crude product of Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate having high conversion rate and low color, and the crude product further undergoes a purification process for crystallization, filtering and drying to obtain a product of Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate having high purity and low color.Type: GrantFiled: August 3, 2009Date of Patent: February 18, 2014Assignee: Nan Ya Plastics CorporationInventors: Dein-Run Fung, Jung-Jen Chuang, Zhang-Jian Huang, Chung-Yu Chen
-
Patent number: 8653301Abstract: A novel tricyclodecane monomethanol monocarboxylic acid and derivatives thereof, which can be raw materials for highly heat-resistant alicyclic polyesters, are provided. A tricyclodecane monomethanol monocarboxylic acid represented by the following formula (I) and derivatives thereof.Type: GrantFiled: July 9, 2010Date of Patent: February 18, 2014Assignees: Hitachi Chemical Company, Ltd., National Institute of Advanced Industrial Science and TechnologyInventor: Hiroyuki Kawakami
-
Patent number: 8653302Abstract: Novel processes for preparing poly(pentafluorosulfanyl)aromatic compounds are disclosed. Processes include reacting an aryl sulfur compound with a halogen and a fluoro salt to form a poly(halotetrafluorosulfanyl)aromatic compound. The poly(halotetrafluorosulfanyl)aromatic compound is reacted with a fluoride source to form a target poly(pentafluorosulfanyl)aromatic compound.Type: GrantFiled: September 21, 2009Date of Patent: February 18, 2014Assignee: UBE Industries, Ltd.Inventor: Teruo Umemoto
-
Patent number: 8653303Abstract: In one embodiment, the invention is to a process for producing acetic anhydride. The process includes at least a step of carbonylating methanol and/or a methanol derivative with carbon monoxide to form acetic acid, and contacting ketene with the acetic acid to form a crude acetic anhydride product stream and a vent stream having unreacted ketene. The process further comprises a step of directing at least a portion of the vent stream to a liquid ring vacuum compressor having a ring seal fluid comprising acetic acid The unreacted ketene in the portion of the vent stream contacts the ring seal fluid to form supplemental acetic anhydride.Type: GrantFiled: January 26, 2012Date of Patent: February 18, 2014Assignee: Celanese International CorporationInventors: R. Jay Warner, Melchoir Meilchen
-
Patent number: 8653304Abstract: A 2,3-dihydro-1H-indene-2-yl urea represented by Formula (Ia) or a pharmaceutically acceptable salt thereof:Type: GrantFiled: September 30, 2010Date of Patent: February 18, 2014Assignee: Toray Industries, Inc.Inventors: Hiroaki Kaneko, Hideki Kawai, Yosuke Iura, Hideki Inoue, Mie Kaino, Hiroyuki Meguro, Tazuru Uchida
-
Patent number: 8653305Abstract: Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a substituent(s), or a heterocylcic group which contains at least one nitrogen atom and which may have a substituent(s); n represents 0 to 3, and when n is 2 or more, a plurality of ring A's may be the same or different from one another); a salt, an N-oxide form, a solvate, or a prodrug thereof; and a medicament which includes those. The compound of formula (I) is capable of binding S1P receptors (in particular, EDG-1 and/or EDG-6), and useful for preventing and/or treating rejection in transplantation, autoimmune diseases, allergic diseases, etc.Type: GrantFiled: September 7, 2011Date of Patent: February 18, 2014Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Hiromu Habashita, Shinji Nakade
-
Patent number: 8653306Abstract: An improved method for the production of 2-amino-1,3-propanediol (serinol) and its bis-adduct, 2,2?-iminobis-1,3-propanediol, from dihydroxyacetone and ammonia in the presence of a hydrogenation catalyst such as Raney nickel, followed by separation using an acidic ion-exchange resin.Type: GrantFiled: December 21, 2012Date of Patent: February 18, 2014Assignee: Penn A Kem LLCInventors: Shridhar G. Hegde, Lei Zhao